34 results about "CXCR4 Inhibitor" patented technology

Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy.

Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.

The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.

The present invention provides compounds, compositions thereof, and methods of using the same.

This invention relates to CXCR4 inhibitors and their use in treating and/or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting tumor vascularization, and corneal and iris neovascularization.

The present invention provides compounds, compositions thereof, and methods of using the same.

The invention relates to inhibition of SDF-1α expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder.

Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.

The invention provides a pyridine heterocyclic compound and application thereof serving as a CXCR4 inhibitor. The structure of the heterocyclic compound and the pharmaceutically acceptable salt, isotope, isomer and crystal form thereof is as shown in general formula I. The heterocyclic compound has CXCR4 signal channel inhibitory activity. The heterocyclic compound with the CXCR4 signal channel inhibitory activity can serve as the effective antagonist of CXCR4 signal channels and can be used for treating or preventing diseases responding to CXCR4 receptor antagonism.

The present invention provides a heterocyclic compound having CXCR4 signaling pathway inhibitory activity, and a pharmaceutically acceptable salt, an isotope, an isomer and a crystal form structure thereof, wherein the compound has a structure represented by a general formula I defined in the specification. The present invention further provides applications of the heterocyclic compound having CXCR4 signaling pathway inhibitory activity. According to the present invention, the heterocyclic compound having CXCR4 signaling pathway inhibitory activity, as the effective antagonist of the CXCR4 signaling pathway, can be used for treating or preventing diseases responsive to CXCR4 receptor antagonism.

The present invention relates to compounds and methods useful for modulation, e.g. inhibition, of C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the compositions in the treatment of various disorders.

The present invention provides a method for inhibiting lymphangiogenesis in a subject, comprising administering a therapeutically effective amount of a CXCR4 inhibitor and/or a CXCL12 inhibitor to the subject. The invention further provides a method for inhibiting tumor lymphatic metastasis in a cancer patient, comprising administering to the subject (a) a therapeutically effective amount of a CXCR4 inhibitor and/or a CXCL12 inhibitor, in combination with (b) a therapeutically effective amount of a VEGF-C inhibitor and/or a VEGF-D inhibitor and/or a VEGFR-3 inhibitor.

The present invention relates to compounds and methods for inhibiting the C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

The present invention provides deuterium-enriched CXCR4 inhibitors, pharmaceutical compositions, and methods of using such deuterium-enriched CXCR4 inhibitors and pharmaceutical compositions to treat, prevent, or ameliorate a disease, disorder, or condition such as cancer or WHIM syndrome.